XML 18 R5.htm IDEA: XBRL DOCUMENT v3.26.1
Condensed Consolidated Statements of Stockholders' Equity - USD ($)
shares in Thousands, $ in Thousands
Common Stock
Additional Paid-in Capital
Accumulated Other Comprehensive Loss
Accumulated Deficit
Total
Equity, beginning balance at Jun. 30, 2024 $ 9 $ 335,162   $ (313,847) $ 21,324
Equity, beginning balance (shares) at Jun. 30, 2024 8,624        
Common stock issued 4     4
Common stock issued (shares) 2        
Vesting of RSUs        
Vesting of RSUs (shares) 12        
Share-based compensation   415     415
Net loss       (3,989) (3,989)
Equity, ending balance at Sep. 30, 2024 $ 9 335,581   (317,836) 17,754
Equity, ending balance (shares) at Sep. 30, 2024 8,638        
Equity, beginning balance at Jun. 30, 2024 $ 9 335,162   (313,847) 21,324
Equity, beginning balance (shares) at Jun. 30, 2024 8,624        
Net loss         (13,214)
Equity, ending balance at Mar. 31, 2025 $ 10 338,432   (327,061) 11,381
Equity, ending balance (shares) at Mar. 31, 2025 10,067        
Equity, beginning balance at Sep. 30, 2024 $ 9 335,581   (317,836) 17,754
Equity, beginning balance (shares) at Sep. 30, 2024 8,638        
Common stock issued (1)     (1)
Common stock issued (shares) 500        
Exercise of stock options 31     31
Exercise of stock options (shares) 18        
Vesting of RSUs        
Vesting of RSUs (shares) 12        
Share-based compensation   475     475
Net loss       (4,364) (4,364)
Equity, ending balance at Dec. 31, 2024 $ 9 336,086   (322,200) 13,895
Equity, ending balance (shares) at Dec. 31, 2024 9,168        
Common stock issued $ 1 1,127     1,128
Common stock issued (shares) 586        
Exercise of stock options   99     99
Exercise of stock options (shares) 55        
Vesting of RSUs (shares) 12        
Share-based compensation   370     370
AstrialBio Exclusive License Agreement shares issued   750     750
AstrialBio Exclusive License Agreement shares issued (shares) 246        
Net loss       (4,861) (4,861)
Equity, ending balance at Mar. 31, 2025 $ 10 338,432   (327,061) 11,381
Equity, ending balance (shares) at Mar. 31, 2025 10,067        
Equity, beginning balance at Jun. 30, 2025 $ 19 347,085   (332,224) 14,880
Equity, beginning balance (shares) at Jun. 30, 2025 19,349        
Common stock issued $ 1 218     219
Common stock issued (shares) 905        
Vesting of RSUs      
Vesting of RSUs (shares)        
Share-based compensation   323     323
Issuance of pre-funded warrants   46,352     46,352
Unrealized loss on available-for-sale debt securities     $ (15)   (15)
Net loss       (5,720) (5,720)
Equity, ending balance at Sep. 30, 2025 $ 20 393,978 (15) (337,944) 56,039
Equity, ending balance (shares) at Sep. 30, 2025 20,254        
Equity, beginning balance at Jun. 30, 2025 $ 19 347,085   (332,224) 14,880
Equity, beginning balance (shares) at Jun. 30, 2025 19,349        
Net loss         (22,443)
Equity, ending balance at Mar. 31, 2026 $ 35 432,190 (21) (354,667) 77,537
Equity, ending balance (shares) at Mar. 31, 2026 34,543        
Equity, beginning balance at Sep. 30, 2025 $ 20 393,978 (15) (337,944) 56,039
Equity, beginning balance (shares) at Sep. 30, 2025 20,254        
Common stock issued $ 10 3,641     3,651
Common stock issued (shares) 9,798        
Share-based compensation   253     253
Issuance of pre-funded warrants   5,585     5,585
Unrealized loss on available-for-sale debt securities     25   25
Net loss       (8,993) (8,993)
Equity, ending balance at Dec. 31, 2025 $ 30 403,457 10 (346,937) 56,560
Equity, ending balance (shares) at Dec. 31, 2025 30,052        
Common stock issued $ 5 4,813     4,818
Common stock issued (shares) 4,491        
Share-based compensation   377     377
Issuance of pre-funded warrants   23,543     23,543
Unrealized loss on available-for-sale debt securities     (31)   (31)
Net loss       (7,730) (7,730)
Equity, ending balance at Mar. 31, 2026 $ 35 $ 432,190 $ (21) $ (354,667) $ 77,537
Equity, ending balance (shares) at Mar. 31, 2026 34,543